These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15555726)

  • 21. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
    Giger JN; Davidhizar R; Poole VL
    J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
    [No Abstract]   [Full Text] [Related]  

  • 23. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.
    Ulloa RE; Nicolini H; Avila M; Fernández-Guasti A
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):85-96. PubMed ID: 17343556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.
    Flament MF; Rapoport JL; Berg CJ; Sceery W; Kilts C; Mellström B; Linnoila M
    Arch Gen Psychiatry; 1985 Oct; 42(10):977-83. PubMed ID: 3899048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
    Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
    J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].
    Kordon A; Zurowski B; Wahl K; Hohagen F
    Nervenarzt; 2011 Mar; 82(3):319-20, 322-4. PubMed ID: 21340636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder].
    Brochier T; Hantouche E
    Encephale; 1989; 15(3):325-33. PubMed ID: 8641159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment for late-onset obsessive-compulsive disorder with parkinsonism.
    Agarwal A; Biswas D; Sadhu R
    J Neuropsychiatry Clin Neurosci; 2008; 20(3):331-6. PubMed ID: 18806237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.
    Kayser RR
    J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926602
    [No Abstract]   [Full Text] [Related]  

  • 33. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder.
    Iwata Y; Kotani Y; Hoshino R; Takei N; Iyo M; Mori N
    J Clin Psychiatry; 2000 Jul; 61(7):528-9. PubMed ID: 10937614
    [No Abstract]   [Full Text] [Related]  

  • 34. Concerns regarding study of obsessive-compulsive disorder in dogs.
    Overall KL
    J Am Vet Med Assoc; 1998 Jul; 213(2):198-9. PubMed ID: 9676584
    [No Abstract]   [Full Text] [Related]  

  • 35. Aggravation of schizophrenia by clomipramine in a patient with comorbid obsessive-compulsive disorder.
    Margetić B; Aukst-Margetić B; Jakovljević M
    Psychopharmacol Bull; 2008; 41(2):9-11. PubMed ID: 18668013
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological treatments for obsessive-compulsive disorder in children and adolescents: a qualitative review.
    Rosa-Alcázar AI; Iniesta-Sepúlveda M; Rosa-Alcázar A
    Actas Esp Psiquiatr; 2013; 41(3):196-203. PubMed ID: 23803803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.
    Friedman S; Abdallah TA; Oumaya M; Rouillon F; Guelfi JD
    J Clin Psychiatry; 2007 Jun; 68(6):972-3. PubMed ID: 17592930
    [No Abstract]   [Full Text] [Related]  

  • 38. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications.
    Moshe K; Iulian I; Seth K; Eli L; Joseph Z
    Clin Neuropharmacol; 1994 Aug; 17(4):338-43. PubMed ID: 9316681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder.
    Kumar TC; Khanna S
    Aust N Z J Psychiatry; 2000 Jun; 34(3):527-8. PubMed ID: 10881981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.